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A B S T R A C T
Malignant testicular germ cell tumors (TGCTs) are the most frequent testicular cancers in Caucasian males,
developing at the most productive age of man. We are brieﬂy reviewing TGCT-tumorigenesis with an emphasis
on epigenetics. Epigenetic mechanisms such as DNA methylation and histone modiﬁcations together with RNA
interference that all change gene expression are driving early spermatogenesis. Deregulation of normal devel-
opment might lead to a testicular germ cell neoplasia in situ (GCNIS), from which TGCTs originate. The
breakthrough epigenetic research, both in normal development and TGCT tumorigenesis, has been going on to
ﬁnd better biomarkers and therapy for this type of tumors.
1. Introduction
Malignant testicular germ cell tumors (TGCTs) are the most frequent
testicular cancers in Caucasian males which make a total of 95% of all
testicular tumors. A 70% increasing incidence in the last 20 years is
probably due to combined action of (epi)genetic and (micro)environ-
mental factors. They are clinically very important because they occur
most often between 20 and 45 years, the most productive age of man
(Elzinga-Tinke et al., 2015). Their incidence has doubled in the last
40 years with recorded annual growth of 3–6% among the Caucasian
population. The incidence of these tumors is highest in northern
Europe, such as in Denmark and Sweden, while it is relatively low in
Africa. We have recently shown that Croatian population has an in-
termediate incidence rate compared to other European or European
ancestry populations, but exerts a rapid and constant incidence increase
instead (Sincic et al., 2012). Namely, while some authors suggest tes-
ticular neoplasms incidence rates may have leveled oﬀ or even shown
signs of decline in certain populations (Holmes Jr et al., 2008; Znaor
et al., 2014) temporal data for Croatian population showed no such
eﬀect. Instead, testicular neoplasms incidence was found steadily in-
creasing and possibly with the steepest increase reported worldwide
(Sincic et al., 2012). Indeed, model-based predictions in 40 countries,
using population-based registry data, estimated that around one in 100
men would be diagnosed with testicular neoplasm annually in three
highest risk countries of Europe among which is Croatia (Le Cornet
et al., 2014). By the year 2026, Hispanics will have the highest rate of
TGCT of any racial or ethnic group in the USA (Ghazarian et al., 2017).
Germ cell tumors of the testis (TGCT) are histologically divided into
two main types of tumors, seminomas, and nonseminomas. Seminomas
usually develop in the later stages of life, in the fourth and ﬁfth decade,
and are composed of a homogeneous population of neoplastic gono-
cytes. Nonseminomas occur among young men between the second and
third decades of life and are more aggressive with heterogeneous his-
tological features, including partially diﬀerentiated populations such as
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teratomas, yolk sac tumors and choriocarcinomas (Mikuz, 2015).
Nonseminomas may contain a pluripotent component known as em-
bryonal carcinoma (EC). EC cells are considered to be a malignant
variant of embryonic stem cells (ES) because they share many mor-
phological and biochemical features of the cells derived from the inner
cell mass (Andrews et al., 2005) The ﬁrst large-scale quantitative pro-
teomic study of human embryonic stem cell-line (ESC-line) and em-
bryonal carcinoma cell-line (ECC-line pointed to the possible regulators
of these two related stem cells (Chaerkady et al., 2010). TGCT semi-
nomas typically express SOX17 in their nuclei and are negative for
SOX2, while embryonal carcinomas express SOX2 and are negative for
SOX17. Both types of tumors express OCT3/4 and NANOG (Nonaka,
2009; Santagata et al., 2007).
Since spermatids and spermatozoa do not proliferate, TGCTs should
arise from their precursors, cells that are mitotically active, such as
primordial germ cells (PGCs) arising from the epiblast or gonocytes that
have settled within the genital ridge (Osterhuis and Looijenga, 2005).
According to the testicular dysgenesis syndrome (TDS) hypothesis, only
cases with pre- or perinatal testicular dysgenesis may suﬀer from tes-
ticular cancer or infertility later in life (Meyts et al., 2013). It has been
widely acknowledged that TGCTs, with the exeption of the spermato-
cytic tumor, arise from residual immature fetal germ cells within the
adult seminiferous tubules. By the latest WHO classiﬁcation, this al-
teration is called “Testicular germ cell neoplasia in situ (GCNIS)” (Moch
et al., 2016) formerly called “Intratubular germ cell neoplasia of the
unclassiﬁed type (IGCNU)” or “Carcinoma in Situ (CIS)” (Damjanov and
Mikuz, 2013; Berney et al., 2016; Almstrup et al., 2011). We shall use
the term GCNIS in the rest of the text, regardless of the expression used
in original articles. For recognition of GCNIS immunohistochemical
(IHC) staining of placental alkaline phosphatase (PLAP) (Fig. 1A and B),
OCT4, AP2gamma, M2A/D240/PDPN or LIN28 are being used (Rajpert-
De Meyts and Skakkebaek, 1994). In a recent clinical study on Disorders
of sexual development (DSD) children it was proposed to diﬀerentiate
between delayed germ cell maturation with lower or no neoplastic
potential and infantile GCNIS with a high risk of malignant evolution
using a triad: OCT 3/4 expression, quantiﬁcation of germ cell atypia
and ploidy in dysgenetic testes (Chemes et al., 2015).
The aim of this article is to brieﬂy review TGCT tumorigenesis with
an emphasis on aberrant epigenetic mechanisms, lately in focus of a
breakthrough research that opens new possibilities in diagnostics and
therapy of a wide variety of tumors (Feinberg et al., 2016).
2. Embryological frame of testicular germ cell tumors
development
The primordial germ cells (PGCs) are the precursor germ cells
arising from the pluripotent embryonic stem cells and can be identiﬁed
in the human embryo already at the gestational age of ﬁve to six weeks
(Donovan, 1994; McLaren, 2003). Led by the KIT ligand and its receptor
and by the chemokine SDF1 and its receptor CXCR4, PGCs travel from
the proximal epiblast through the mesentery to the genital ridge and
become gonocytes (Donovan, 1994; Godin et al., 1991; Runyan et al.,
2006). PGCs and gonocytes can be identiﬁed by the stem cell markers
PLAP, NANOG, KIT, SOX2 (mouse) or SOX17 (human), AP2γ, SALL4,
POU5F1 (OCT3/4) (Wylie, 1993; de Jong et al., 2008; Gashaw et al.,
2007; Gaskell et al., 2004; Honecker et al., 2004; Kerr et al., 2008;
Wong et al., 2008; Wu et al., 2006).
In the presence of the Y chromosome, gonadal stem cells express the
transcription factor SRY targeting SOX9 gene which leads to the growth
of Sertoli cells (Vigueras-Villasenor et al., 2015). Sertoli cells create the
microenvironment required for diﬀerentiation of gonocytes to pros-
permatogonia and spermatogonia. During the process of diﬀerentiation,
some genes become expressed (e.g., MAGE4A), and some are silenced
(Gashaw et al., 2007; Gaskell et al., 2004; Wong et al., 2008; Vigueras-
Villasenor et al., 2015; Cao et al., 2009). At that time, malignant
transformation within the seminiferous tubules can occur. GCNIS
(Figs. 1A, B, 2A) is considered to be a precursor lesion of most germ cell
tumors, a predecessor of seminoma (Figs. 1C, D and 2C) and non-
seminoma. If GCNIS retains its phenotype and its cells continue to di-
vide similarly as spermatogonia or fetal spermatocytes, a seminoma
tumor will arise. If, however, GCNIS cells are transformed into em-
bryonic cells, the nonseminoma tumors of reproductive cells arise. It is
of a fundamental biological interest to understand why and how dif-
ferent tumors can seemingly arise from the cells of the same type.
Nonseminomas can be divided into several types of tumors: em-
bryonal carcinoma (Figs. 2D, 3A and B), teratoma (Fig. 3C), yolk sac
tumor (Fig. 3D) and choriocarcinoma (Sheikine et al., 2012). Some-
times mixed forms can be found (Fig. 2B). Embryonal carcinoma is the
most common nonseminoma tumor and occurs in 87% of cases (Bosl
and Motzer, 1997). The only testicular germ cell tumor (TGCT) not
Fig. 1. Histology of testicular germ cell neoplasia in
situ and seminoma. A) Seminiferous tubules with
germ cell neoplasia in situ (GCNIS) (arrow); HEx200.
B) Immunostaining showing positive cells of germ
cell neoplasia in situ; anti-PLAP, DAB, counterstained
with hematoxylinx200. C) Seminoma; HEx100. D)
Seminoma. Positive immunostaining for PLAP; anti-
PLAP, DAB, counterstained with hematoxylinx100.
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associated with GCNIS but possibly with spermatogonial stem cells is
the spermatocytic seminoma that has recently changed its name to the
spermatocytic tumor (Moch et al., 2016; Waheeb and Hofmann, 2011;
Osterhuis and Looijenga, 2005). A widely accepted theory of GCNIS
tumorigenesis is that it starts in utero, under the inﬂuence of important
predisposing factors, such as an increased level of the maternal estrogen
or in the presence of environmental toxins. Disruption of germ cell
development leads to the arrest of fetal stem cells. It seems that the
inﬂuence of hormones potentiates the proliferation of dormant GCNIS
cells during adolescence and young adulthood. Progression and the
development of invasive forms of TGTCs are what can follow (Depue
et al., 1983; Swerdlow et al., 1987).
Experiments dealing with transplantation of the mice embryo parts
from which PGCs originate (e.g., epiblast, early primitive-streak em-
bryo) to ectopic sites in vivo resulted in the development of teratoma
and teratocarcinoma. Teratocarcinoma contained derivatives of three
germ layers together with malignant embryonal carcinoma cells (ECCs)
(Solter et al., 1970; Bulic-Jakus et al., 2016). Already in 1981, N. Škreb
assumed that these could be “tumors without mutation” (Skreb, 1981).
In other words, only the changes in gene expression could lead normal
gastrulating embryos to acquire a malignant phenotype. So, for decades
epigenetic cues arising from the ectopic environment were thought to
be the only cause for the development of malignant cells within the
diﬀerentiated tissue derivatives (Solter et al., 1970; Bulic-Jakus et al.,
2016; Skreb, 1981). Indeed, “recent investigations of a variety of pe-
diatric cancers have surprisingly identiﬁed tumor types with few or no
Fig. 2. Expression of pluripotency and stemness
marker OCT3/4. A) Seminiferous tubules with posi-
tive cells of the germ cell neoplasia in situ (GCNIS);
anti-OCT3/4, DAB, counterstained with hematox-
ylinx200. B) Mixed form consisting of seminoma
(thick arrow) and embryonal carcinoma (EC) (thin
arrow); anti-OCT3/4, DAB, counterstained with
hematoxylinX100. C) Seminoma; anti-OCT3/4, DAB,
counterstained with hematoxylinx400. D)
Embryonal carcinoma; anti-OCT3/4, DAB, counter-
stained with hematoxylinx200.
Fig. 3. Histology of testicular embryonal carcinoma,
teratoma and yolk sac tumor. A) Embryonal carci-
noma with numerous mitotic ﬁgures (arrow);
HEx200. B) Immunostaining showing positive EC
cells; anti-OCT3/4, DAB, counterstained with he-
matoxylinx100. C) Teratoma with cartilage (asterisk)
and cystic structures lined by pseudostratiﬁed epi-
thelial cells; HEx100. D) Yolk sac tumor; HEx200.
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mutations, suggesting that epigenetic derangements can themselves
drive these cancers” (Feinberg et al., 2016).
Moreover, above mentioned results of ectopic transplantation in the
mouse speak for the embryonic origin of teratocarcinoma, even at an
earlier stage of development - before the formation of genital ridges
(Bulic-Jakus et al., 2016). Human pluripotent germ cell lines (hPGCs)
were derived from the genital ridges and were characterized in vitro but
failed to produce teratomas after transplantation to the im-
munocompromised mice in vivo in contrast to mouse embryonic stem
cells (Shamblott et al., 1998; Shamblott et al., 2001). It was stated that
in the absence of the deﬁnitive chimeric experiment, the in vivo plur-
ipotency of human embryonic germ cells remains unresolved. Con-
sidering a possible therapeutic eﬀect of human embryonic germ cells
(hEGCs) derived in vitro from PGCs, the lack of teratoma formation
should be desirable for therapy in human recipients (Turnpenny et al.,
2006).
3. Risk factors
The exact etiology of the TGCTs is still unknown, but the geographic
and racial diﬀerences in its prevalence suggest that the causes may lie
in the environment or that the disease is genetic in nature. For now, risk
factors include cryptorchidism, gonadal dysgenesis, TGCT in the con-
tralateral testicle, infertility, family history, testicular microlithiasis and
environmental factors. Persons with cryptorchidism suﬀer from testi-
cular cancer ten times more often than those with the normal descensus
testis. Surgical orchidopexy does not diminish the risk (Mikuz, 2015).
Testicular microlithiasis is a condition characterized by deposits of
calcium which is associated with the possible occurrence of testicular
malignancy, especially its familial form (Korde et al., 2008; Greene
et al., 2010). Environmental factors such as the prenatal exposure to
diethylstilbestrol were shown to increase the relative risk of TGCT from
2.8 to 5.3% (Berney et al., 2016).
However, accordingly to the recent systematic review, not so many
epidemiological studies investigated the impact of parental occupa-
tional or environmental exposure, and results were inconsistent.
According to the authors, many occupational exposures during adult-
hood cannot be clearly associated with TGCT etiology, which might
also be in line with the current hypothesis of prenatal and/or early-life
origin of TGCT (Béranger et al., 2013). However, the question of par-
ental exposure is not likely to be disregarded because e.g., an in-
vestigation of parental exposure to heavy metals/welding fumes and
TGCT in oﬀspring has recently highlighted a possible association of
TGCTs and high paternal chromium exposure (Togawa et al., 2016).
On the other hand, family history of TGCTs is one of the strongest
and most consistent risk factors for these cancers. Patient's brothers
have eight to ten times higher relative risk compared to the general
population, fathers four times and sons six times (Greene et al., 2010;
Béranger et al., 2013; Dong and Hemminki, 2001; Hemminki and Li,
2004).
Therefore it seems that both, the inherited susceptibility and en-
vironmental factors, may be involved in the development of the disease.
The genvironmental hypothesis assumes an interaction between en-
vironmental and (epi)genetic parameters inﬂuencing developmental
processes during early spermatogenesis (proliferation, diﬀerentiation,
apoptosis) through aberrations in signaling pathways (Looijenga et al.,
2013).
4. Genetic hypotheses
Somatic mutations that may lead to the development of germ cell
tumors include the deletion of genes, chromosomal duplication, and
loss of heterozygosity (Depue et al., 1983). Mutations in single genes
are not common for TGCTs. Nonseminomas are typically hypotriploid
and seminomas usually hypertriploid (Gilbert et al., 2011). Iso-
chromosome 12p is the most common alteration, which can be found in
80% of cases in seminomas and nonseminomas. However, the existence
of this alteration is not necessarily required for the development of the
tumor (Looijenga et al., 2003).
Although point mutations of genes are rare, KIT, TP53, KRAS/BRAF
and NRAS, that are also involved in the pathogenesis of other cancers,
were found to be mutated in TGCTs (Gonzalez-Exposito et al., 2016).
The most commonly mutated gene in TGCTs is the proto-oncogene KIT,
located on chromosome 4q11-q12. KIT is the stem cell growth factor, a
tyrosine kinase receptor that is phosphorylated upon binding to its li-
gand (KITLG) and has a crucial role in the survival, proliferation, and
migration of the germ cells (Besmer et al., 1986; Flanagan et al., 1991;
Yarden et al., 1987). Spermatogonia express KIT at a low level, while it
is well expressed in all GCNIS, most seminomas, and some non-
seminomas (Biermann et al., 2012). It is assumed that the production of
KIT by malignant cells is a temporary autocrine and paracrine stimu-
lation of tumor cell growth. KIT gene is mutated in 19% of seminomas
and 2% of non-seminoma tumors. Two studies have shown a sig-
niﬁcantly higher percentage of KIT gene mutations in patients with
bilateral TGCT, 93% versus 63.6% (Rajpert-De Meyts and Skakkebaek,
1994; Kemmer et al., 2004; Madani et al., 2003).
In TGCT, predisposing single nucleotide polymorphisms (SNPs) such
as 5q31, 9p24 and 12q21 were conﬁrmed in several independent stu-
dies. 12q21 locus has a signiﬁcantly lower incidence in African-
Americans compared to the white population, which could potentially
explain a signiﬁcantly lower incidence of TGCTs in African-Americans
(Gajendran et al., 2005; McGlynn et al., 2005). Products of genes lo-
cated in these loci participate as inhibitors of mitogens and as pro-
moters of apoptosis. All these genomic variants are believed to parti-
cipate in the KITLG/KIT signaling pathway (Yan et al., 2000) which is
very sensitive to oncogenic stimuli. Although these SNPs are biologi-
cally important, they took part in only 15% of the family risk (Turnbull
and Rahman, 2011). It has been shown that the development of the
GCNIS may involve aberrant activation of the KITLG/KIT pathway and
excessive expression of embryonic transcription factors such as the
NANOG and POU5F1, suppressing apoptosis, increasing cell prolifera-
tion and accumulating mutations in the gonocytes. In addition to the
genes whose mutations lead to a change of the cell cycle, mutations in
genes encoding for the estrogen receptors have been found. It has been
shown that ER alpha gene polymorphism is associated with azoos-
permia and the risk for seminoma and metastases (Brokken et al., 2012;
Romerius et al., 2011). Two recent meta-analyses of GWAS studies,
published in 2017, identiﬁed multiple new SNP-loci associated with
TGCTs. In the Testicular Cancer Consortium study some of previously
reported markers could not be identiﬁed, possibly also due to the re-
sidual population substructure. Racial diﬀerences were again noted to
parallel population-speciﬁc TGCT risk. The 12 new markers that were
identiﬁed increased estimation of heritability to 25% for brothers and
37% for sons (Wang et al., 2017). The second study of Litchﬁeld et al.
suggests also a polygenic model of TGCT susceptibility with transcrip-
tional dysregulation, developmental arrest of primordial germ cells,
chromosomal instability through defective microtubule function and
upregulation of KIT–MAPK signaling (Litchﬁeld et al., 2017).
A diﬀerence in structural genetic alterations for genes involved in
the malignant tumor phenotype occurrence between seminomas and
nonseminomas has recently been observed (Vladusic et al., 2014). The
ﬁrst report on exome sequencing of seminomas detected somatic mu-
tations in almost a hundred new genes, several of which may present
driver mutations. Although seminoma mutation rates were found to be
ﬁve times higher than previously thought, they were lower than in
other common cancers (Cutcutache et al., 2015).
5. Epigenetic breakthrough
Epigenetics is a rapidly developing discipline in biology that studies
mechanisms leading to changes in the gene expression that are not
caused by a change in the sequence of the DNA molecule per se.
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Epigenetic mechanisms play a major role in cellular processes such as
cell diﬀerentiation, apoptosis, and DNA repair which are compromised
in tumorigenesis.
5.1. Epigenetics and cancer
Most epigenetic signatures are established during diﬀerentiation
and are held stable through multiple cycles of division, allowing the
cells to have a diﬀerent function while containing the same genetic
information. Heritability of gene expression patterns is mediated by
epigenetic modiﬁcations, which include the methylation of cytosine
bases in the DNA, posttranslational modiﬁcations of histone proteins
and reorganization of the chromatin. Failure to maintain proper her-
editary epigenetic code caused by epimutations can result in in-
appropriate activation or inhibition of a variety of signaling pathways
leading to diseases such as the carcinoma (Sincic and Herceg, 2011).
Epimutation, such as an aberrant promoter methylation, can result in
the silencing of tumor suppressor genes. It may act in combination with
harmful genetic mutation as a second hit required for initiation of
cancer in agreement with the Alfred Knudson's “two-hit” hypothesis
(Ellinger et al., 2009; Manton et al., 2005). Epimutations can lead to
tumorigenesis also by the activation of oncogenes. Endogenous condi-
tions may induce methylation of promoter regions of certain genes
through estrogen or androgen inhibitors (Brait et al., 2008).
Methylation of the DNA molecule was ﬁrst described, and it is the
most explored among epigenetic modiﬁcations (Sincic and Herceg,
2011; Serman et al., 2006). It represents a covalent addition of methyl
groups to cytosine in a cytosine ring-guanine dinucleotide complex
(CpG). Methylation is catalyzed by DNA methyltransferase (DNMTs),
which converts a cytosine to 5‑methylcytosine (5mC). DNA methylation
marks are usually located near or within the promoter region of the
gene. DNA methylation can cause gene silencing, directly interfere with
the DNA binding of speciﬁc transcription factors or by binding of the
Methyl-CpG-a coupling protein (MBDs) that inhibit expression of genes
by chromatin remodeling (Jones et al., 1998; Wade, 2001). Another
frequent epigenetic modiﬁcation is the posttranslational modiﬁcation
of histone proteins. Histones are basic proteins possessing the ﬂexible
N-terminal tail which is protruding from the nucleosome and represent
the main target for modiﬁcations such as the acetylation and methy-
lation. Acetylation is controlled by the balanced activity of histone
acetyltransferase (HAT) that is adding an acetyl group at the N-ter-
minus of lysine, while histone deacetylases (HDACs) have the opposite
role. Transcriptional regulation is quite direct, acetylation of histones
results in chromatin unfolding and gene transcription (Iizuka and
Smith, 2003). Histone methylation also regulates gene expression. An
addition of the methyl group to the N-terminal lysine is associated with
either the transcriptional activity or non-activity, depending on which
amino acid is modiﬁed (Santos-Rosa and Caldas, 2005). Some other
posttranslational histone modiﬁcations can also change gene activity
(Bannister and Kouzarides, 2011). The third mechanism involved in
regulation of gene activity is the mechanism of RNA interference aimed
at the destruction of speciﬁc mRNA molecules at the posttranscriptional
level. It is executed by the noncoding RNAs such as microRNA, siRNA
that have lately been investigated in the context of cancerogenesis and
possible clinical application (biomarkers, novel therapeutics) (Hirsl
et al., 2014; Hayes et al., 2014). Small RNAs, including microRNAs
(miRNAs), endogenous small interfering RNAs (endo-siRNAs) and PIWI-
interacting RNAs (piRNAs) that are involved in the control of male
gamete diﬀerentiation may also participate in TGTCs tumorigenesis
(Meikar et al., 2013).
Recently, even the genes that are mutated in cancer have been
classiﬁed accordingly to their role in cancer epigenetics. “Epigenetic
mediators” that are corresponding to the tumor progenitor genes, rarely
mutated or not mutated, increase pluripotency or survival (e.g., OCT4,
NANOG, LIN28, SOX2, KLF4). “Epigenetic modiﬁers” of the mediators
are frequently mutated in cancer (e.g., SMARCA4, PBRM1, ARID1A,
ARID2, ARID1B, DNMT3A, TET2, MLL1/2/3, NSD1/2, SETD2, EZH2,
BRD4). “Epigenetic modulators”, upstream of the modiﬁers, are re-
sponsive to changes in the cellular environment and are often linked to
the nuclear architecture. Modulators, mutated or not, activate or re-
press the epigenetic machinery in cancer (e.g., IDH1/2, KRAS, APC,
TP53, STAT1/3, YAP1, CTCF) (Feinberg et al., 2016). Therefore, apart
from investigations of gene mutations in TGCTs, it is important to
thoroughly investigate changes in gene expression caused by epigenetic
mechanisms, which are lately found in most, if not all malignant neo-
plasms. Because certain epigenetic marks that compose cell-speciﬁc
epigenetic signatures (Hernandez-Vargas et al., 2009) are necessary for
the maturation of a germ cell, it is believed that precisely their aber-
rations play a major role in the development of germ cell tumors.
5.2. Epigenetics of early development and TGCTs
Migrating PGCs (primordial germ cells) and gonocytes situated in
the male gonad at the gestation week six are undiﬀerentiated em-
bryonic cells which have gone through the process of epigenetic re-
programming which includes erasure and re-establishment of DNA
methylation and exchange of histone modiﬁcations (Kristensen et al.,
2013). DNA demethylation erases the original epigenetic state in go-
nocytes, among which the genomic imprints, that are necessary for the
development of two types of germ cells accordingly to the sex of the
child (Meikar et al., 2013). As has been just said, germ cells, during the
early stages of their development, undergo a phase of generalized DNA
demethylation. This very demethylation can be either passive or active.
The passive form is due to the lack of DNMT reduction that is in charge
of the process of demethylation. As for active demethylation process,
two possible mechanisms are proposed. The ﬁrst initiator of the process
may be the ten-eleven translocation (TET) protein that converts 5mC in
the hydroxymethylated cytosine (5hmC) because expression of TET1
and TET2 coincides with the rapid disappearance of 5mC. Another
possible mechanism can be a direct deamination of the 5mC to T,
mediated by AID/APOBECI. Such deamination induces a mismatch T:G
in the DNA molecule (He et al., 2011; Hajkova et al., 2010; Ito et al.,
2011; Morgan et al., 2004; Iizuka and Smith, 2003; Santos-Rosa and
Caldas, 2005; Bannister and Kouzarides, 2011; Hirsl et al., 2014).
Because in gonocytes the original epigenetic signature becomes
erased, it is possible that an unusual combination of activated and in-
activated genes in gonocytes transforms them into GCNIS. GCNIS de-
velops into seminoma or embryonal carcinoma. Embryonal carcinoma,
being totipotent, can further diﬀerentiate into teratomas (comprising
cells of all three germ layers), yolk-sac tumors and choriocarcinomas
(both comprising extraembryonic tissues). Importantly, it was shown
that TCam-2 seminoma cell line upon xenotransplantation might transit
into EC which is accompanied by considerable remodeling of the me-
thylome. A reprogramming of a seminoma to an embryonal carcinoma
increases the risk of a poor outcome and requires adjustment of the
treatment strategy (Nettersheim et al., 2015).
In comparison to the normal spermatogonia, GCNIS genome re-
mains unmethylated in the adult testis (Nielsen et al., 1974). Morpho-
logical and immunohistochemical studies show that GCNIS cells re-
semble fetal germ cells. GCNIS cells express the transcription factors
POU5F1 (OCT3/4), NANOG, TIA-2, MYCL1, GDF3, DPPA4, KIT and
TFAP2C, associated with the pluripotency of the embryonic stem cells
(Almstrup et al., 2010; Sperger et al., 2003; He et al., 2011). Octamer-
binding transcription factor 4 (OCT4) and SOX2 are transcription fac-
tors that play a key role in maintaining the pluripotency of ES cells.
OCT4 protein, encoded by the gene POU5F1, is critical in the self-re-
generation of undiﬀerentiated embryonic stem cells. Therefore, OCT4 is
often used as a marker of undiﬀerentiated cells. Expression of POU5F1
must be precisely regulated because any error will lead to changes in
diﬀerentiation. Very low levels of DNA methylation are observed in
cells of the GCNIS, but the activity of DNA methyltransferase1 was
demonstrated. Although 5MC and 5hmC were detected in primordial
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germ cells, GCNIS contain very low levels of 5MC and 5hmC in the
absence of TET protein expression. Studies have shown that GCNIS cells
express proteins that facilitate demethylation of DNA, such as the AID/
APOBECI and BER. The same demethylation proteins are expressed in
fetal germ cells but at signiﬁcantly lower levels (Kristensen et al.,
2014). It is believed that the pluripotency genes are associated with
hypomethylation. This facilitates the increased proliferation of the
GCNIS cells that are subjected to an excessive hormone activity in the
post-puberty testis. All these components undoubtedly contribute to the
progression of invasive cancer. The most commonly used marker for
detecting GCNIS is the Placental-like alkaline phosphatase (PLAP)
(Manivel et al., 1987).
Generalized DNA hypomethylation is a feature of fetal germ cells,
but after birth, it changes to hypermethylation in male germ cells.
GCNIS and seminomas have lowest levels of DNA methylation with
relaxed chromatin structure associated with the high transcriptional
activity (Lind et al., 2007). Smiraglia et al. have proposed a model
where seminomas arise from GCNIS cells that emerged from the pri-
mordial germ cells, which have undergone a process of global de-
methylation, while nonseminomas are resulting from GCNIS cells that
have passed through the de novo methylation (Smiraglia et al., 2002).
Indeed, undiﬀerentiated GCTs (seminomas, GCNIS, and gonado-
blastomas) are hypomethylated, whereas more diﬀerentiated GCTs
(teratomas, yolk sac tumors, and choriocarcinomas) show a higher
degree of methylation. Embryonal carcinomas show an intermediate
pattern (Wermann et al., 2010). Diﬀerent extents of methylation in
diﬀerent subtypes of the TGCTs favor the developmental model of male
germ cell tumors origin (Sheikine et al., 2012). Change of the methy-
lation status is linked to a gene that encodes the DNA methyltransferase
3 beta (DNMT3B). It is usually expressed in pluripotent embryonic cells
and induces de novo methylation at that stage of development. Through
DNA methylation, diﬀerentiation of embryonal carcinoma in diﬀerent
subtypes may also be regulated (Sheikine et al., 2012).
So far it was shown that a blocked PGC/gonocyte possesses a bial-
lelic expression of imprinted genes (van Gurp et al., 1994; Verkerk
et al., 1997), demonstrating the erased pattern of genomic imprinting.
A recent study of genome-wide DNA methylation proﬁles of various
germ cell tumors subtypes related them to speciﬁc stages of early de-
veloping embryonic germ cells. Somatic imprinting in TGCTs (be-
longing to the type II germ cell tumors) that was discovered might in-
dicate a cell of origin after global demethylation but before erasure of
imprint. This is earlier than previously described but agrees with the
totipotent/embryonic stem cell-like potential of TGCTs (van Gurp et al.,
1994; Verkerk et al., 1997; Rijlaarsdam et al., 2015).
Global DNA hypomethylation is characterized by a global loss of
5‑methylcytosine (5mC) which contributes to malignant transformation
by activation of oncogenes and latent retrotransposons, such as LINE-1
(long interspersed nuclear element 1). LINE-1 retrotransposons are
highly active in TGCTs and can cause insertional mutagenesis, tran-
scriptional dysregulation, DNA breaks and an increased level of re-
combination. It is believed that such changes in the LINE-1 retro-
transposons contribute to genomic instability and malignant
transformation (Dobrovic and Kristensen, 2009). In a study from 2010
Mirabello and associates showed that LINE-1 methylation level can be
inherited from the parents and that hypomethylation is associated with
risk of testicular cancer (Mirabello et al., 2010). Correlation between
decreased levels of LINE-1 methylation and TGCTs is stronger in pa-
tients with seminoma and patients with bilateral tumors (Mirabello
et al., 2010).
Histone modiﬁcations H3K9me2 and H3K27me3 that are both as-
sociated with a restrictive chromatin structure were expressed in low
levels in GCNIS cells in contrast to H3K4me1, H3K4me2/3, H3K9ac and
a histone variant H2A.Z that are associated with relaxed and permissive
chromatin structure. At the same time, RNA polymerase II was very
active, and cells had a high proliferation rate (Almstrup et al., 2010). A
recent study on 44 independent TGCT risk loci conﬁrmed a signiﬁcant
enrichment of enhancer or promoter associated histone marks
H3K4me1, H3K4me3, H3K9ac in TGCT cell line NTERA 2 that was
tissue speciﬁc in comparison to 41 other cell lines. This was followed by
analysis of expression quantitative trait loci (eQTL) and in situ-chro-
mosome conformation capture in TGCT cells that conﬁrmed physical
interactions of SNPs and candidate causal genes (Litchﬁeld et al., 2017).
Seminomas show high levels of selected repressive modiﬁcations, ex-
empliﬁed by H3K9me2 and H3K27me3. On the other hand, non-
seminomas show high methylation levels (Manivel et al., 1987; Netto
et al., 2008), but the embryonal carcinoma, retains a very open and
fetal-like histone proﬁle (Almstrup et al., 2010).
5.3. Aberrant epigenetic marks in TGCTs
Seminomas show almost no CpG island methylation, while non-
seminomas show the methylation of the same islands at the level of
other solid tumors. Seminomas are more hypomethylated genome-wide
than nonseminoma tumors and hypermethylation in speciﬁc promoter
regions in nonseminomas, in contrast to seminomas was found. Also,
studies of X chromosome showed a weak or a lack of methylation in
seminoma, and higher levels of methylation in nonseminomas, espe-
cially in the diﬀerentiated types (Peltomaki, 1991; Looijenga et al.,
1997). CpG island hypermethylation results in a change in chromatin
structure and lowers the transcription. However, certain studies
(Cheung et al., 2011) show that regardless of the diﬀerent levels of
methylation in diﬀerent genes, only 20% of genes showed an associa-
tion of the hypermethylation and gene activity suppression. DNA me-
thylation is involved in genomic imprinting and X chromosome in-
activation (Wilkins, 2005). There are three types of DNA
methyltransferase. DNMT1 maintains methylation during DNA re-
plication and thus contributes to the stability of gene expression of
parental cells in the daughter cells. In the process of germ cells diﬀer-
entiation, DNMT3A and DNMT3B transfer methyl groups to cytosine
residues. Analyses have recorded an increased level of the DNMT3A
expression in seminoma, while the level of DNMT1 and DNMT3B re-
mains equal. Other studies conﬁrm an increased level of DNMT3B in
non-seminomas (Okada et al., 2003). DNMT3A in healthy tissues pre-
sents a mixture of methylated and unmethylated CpG islands in intron
25, while most of the CpG islands in intron 25 are demethylated in
samples of TGCTs (Chen et al., 2014).
It is believed that an important role in TGCT tumorigenesis has the
epigenetic change in tumor suppressor genes such as RASSF1A.
RASSF1A methylation was detected in 40% seminomas and 83% non-
seminoma TGCT components (Honorio et al., 2003).
Testisin (PRSS21), a Glycosyl-phosphatidylinositol-linked serine
protease, found in premeiotic spermatocytes, promotes malignant
transformation in vivo and in vitro (Tang et al., 2005). Human Testisin
gene is located on chromosome 16 and consists of six exons and ﬁve
introns. It contains a 5′ CpG island and the 5′ CpG rich region. Within
the gene, there are many sites containing CpG dinucleotides that can
potentially be methylated. Downstream, within the ﬁeld of transcrip-
tion, the gene contains CpG dinucleotides, which in the case of me-
thylation can bind Methyl CpG binding protein (MECP), such as MeCP2
and MeCP1 involved in transcription repression (Manton et al., 2005).
A strong association was found between hypermethylation of the 5′
region of the gene and loss of Testisin mRNA expression in tumor cells.
In a recent genome-wide proﬁling PRSS21 was hypermethylated in all
GCTs except spermatocytic tumor (Rijlaarsdam et al., 2015).
Research of Cheung and collaborators from 2011 (Cheung et al.,
2011) identiﬁed the Carcinoma embryonic antigen-like protein Podo-
calyxin-like protein 1 (PODXL1), the anti-adhesive protein expressed in
aggressive tumors, to serve as a target of miR-199a-5p, one of two
mature miRNA species derived from miR-199a. PODXL1 is over-
expressed in malignant testicular tumors, and its cellular depletion re-
sults in suppression of cancer invasion. DNA methylation-linked dys-
regulation of a conserved miR-199a is caused by aberrant methylation
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in an intronic region of DNM3 at 1q24.3. MiR-199a is more methylated
in seminoma than in non-seminoma. Hypermethylation of the DNM3
intron leads to miR-199a repression. Therefore, epigenetic alteration in
DNM3 intron leads to dysregulation of miR-199a and PODXL1, as cri-
tical factors in tumor malignancy (Cheung et al., 2011). As another
direct target of miR-199a-5p, V-maf musculoaponeurotic ﬁbrosarcoma
oncogene homolog B (avian) (MAFB) was postulated. Expression of the
MAFB was the strongest in the cancerous tissue of the testis. An anti-
proliferative role of miR-199a was realized through repression of MAFB
in TGCT. Together with the antiinvasive eﬀect of the PODXLl, miR-199a
acts as a tumor suppressor in TGCT (Gu et al., 2013). DNA (cytosi-
ne‑5)‑methyltransferase 3A (DNMT3A), the de novo methyltransferase,
was identiﬁed as a direct target of the other mature miRNA derivative
miR-199a-3p. Overexpression of miR-199a-3p restored the expression
of APC and MGMT tumor-suppressor genes in Ntera 2 (NT2), cells from
an established pluripotent human testicular embryonal carcinoma cell
line by aﬀecting DNA methylation of their promoter regions (Chen
et al., 2014).
Numerous analyses have shown a similar association between the
combined level of methylation of the promoter region and the risk of
developing seminoma and non-seminoma tumors. In a study from 2012
by Mirabello and collaborators, this connection was discovered and
proved only for a lower level of KITLG promoter methylation in the
development of seminoma and high BAK1 promoter methylation. The
lower level of DND1 promoter methylation was associated with an in-
creased risk of seminoma (Mirabello et al., 2012). Increased methyla-
tion of the promoter region of the gene PDE11, and SPRY4, BAK1 and
reduced promoter methylation of KITLG in primary cells is associated
with an increased risk for the development of familial TGCT (Mirabello
et al., 2012). The promoter region of PDE11 contains 7CpG sites, and
their methylation levels are elevated in all cases of TGCT (Muhlhauser
et al., 1995).
Seminoma and EC showed a hypomethylated upstream region of
OCT3/4 whereas diﬀerentiated non-seminomas, teratoma and yolk sac
tumor, which lack OCT3/4 expression, were found to be hypermethy-
lated in the upstream region (De Jong et al., 2007).
NANOG is an important transcription factor, a key regulator of self-
renewal and maintenance of pluripotency in undiﬀerentiated em-
bryonic stem cells (Muhlhauser et al., 1995; Chambers et al., 2003).
NANOG expression was not observed in the healthy adult testis (Hart
et al., 2005), while it was highly expressed in seminoma and embryonal
carcinoma. NANOG expression is very low in teratomas, yolk sac tu-
mors, choriocarcinomas and mixed nonseminomas. All this speaks in
favor that the CpG methylation in NRR (NANOG regulatory regions)
correlates with NANOG expression in germ cells (Nettersheim et al.,
2011). NRR hypermethylation in sperm and adult healthy testis can be
a way of epigenetic repression of NANOG expression to control plur-
ipotency program and prevent the malignancy of germ cells
(Nettersheim et al., 2011).
Some signaling pathways, such as PIWI/piRNA play a critical role in
the development of male germ cells. Therefore their role in the devel-
opment of testicular germ cell tumors was investigated. It seems that
GCNIS cells and TGCTs do not express PIWI/piRNA pathway genes in
contrast to adjacent normal tissue of the testis (Gainetdinov et al.,
2018). Studies have shown that the methylation of the 5′ promoter
region CpG islands leads to silencing PIWIL1, PIWIL2, PIWIL4, and
TRDI1 gene in primary testicular tumors (Ferreira et al., 2014). The
speciﬁc hypermethylation of CpG islands in those genes is associated
with piRNA which leads to transcriptional inactivation in testicular
cancer. The most important is that the epigenetic inactivation of PIWI-
class proteins and related TDRD1proteins in tumorigenesis occurs in the
context of reduced expression of piRNA and DNA hypomethylation of
LINE 1. Interestingly, epigenetic PIWI protein changes also occur in
male infertility, which associates infertility to testicular cancer
(Hotaling and Walsh, 2009; Peng et al., 2009).
According to a study from 2012, similar methylation pattern in
seminomas, nonseminomas and normal cells of the testes were found in
the following genes: ARF, S100A2, SSBP2, ER-alpha, and ER-beta.
Interestingly, SSBP2 and ER-alpha had a higher degree of methylation in
healthy testicular cells than in the tumor cells. MGMT, VEGF, ER-beta
and FKBP4 were methylated in nonseminoma tumors, in contrast to
seminoma. APC and hMLH1 were methylated in both tumor types, APC
with higher frequency and level of methylation, while hMLH1 only with
higher frequency (Brait et al., 2012).
By a recent genome-wide methylation study of GCT tumors (in-
cluding female tumor types), APC and SOX17 genes were found to be
hypomethylated in all germ cell tumors, including embryonal carci-
noma (EC) and seminoma (SE). AR (androgen receptor) was completely
deprived of methylation in all male tumors and SOX2 was hypo-
methylated in EC and SE tumor samples in contrast to the teratoma
samples which showed higher levels of methylation. For XIST, semi-
noma showed a trend towards less methylation as compared to the
strongly methylated proﬁle of the non-seminomatous tumors
(Rijlaarsdam et al., 2015). Some of these ﬁndings are in contrast to
previous research (e.g., APC), and therefore authors suggest further
validation. In 2004, detection of XIST unmethylated fragment in plasma
was even proposed for diagnostics of TGCTs in males because in TGCT
cases unmethylated XIST DNA signals were signiﬁcantly higher than in
peripheral blood lymphocytes derived from healthy men, with the
highest levels in advanced disease (Kawakami et al., 2004; Looijenga
and Oosterhuis, 2004).
A recent genome-wide analysis of testicular ECs identiﬁed methy-
lation changes in several previously unknown genes. Among the genes
that were hypermethylated in their promoters and consequently of a
downregulated expression, ﬁve were sex-linked genes, including X-
linked genes STAG2, SPANXD/E and MIR1184, and Y-linked genes
RBMY1A1/1B/1D and FAM197Y2P that may provide insight of cross-
talk between normal germ cell development and carcinogenesis
(Cheung et al., 2016).
The gene encoding PRAME, one of cancer/testis antigens, was found
to be hypomethylated at its promotor in seminoma and hypermethy-
lated in EC. Moreover, increased methylation during the in vivo repro-
gramming of a seminoma cell line to EC was detected. Additionally,
PRAME expression was upregulated in EC cell lines after treatment with
histone deacetylase inhibitors (HDIs) that was seemingly able to over-
ride the repressive methylation mark. Knock-down of PRAME expres-
sion led to downregulation of pluripotency and PGC-related genes
(LIN28, PRDM14, and ZSCAN10) and upregulation of somatic (en-
dodermal, mesodermal) and germ cell diﬀerentiation markers
(Nettersheim et al., 2016).
A group of genes associated with the germ cell state and/or plur-
ipotency (PRDM14, TDRD12, DDX43, MNS1, RBMXL2, and Klf4) were
methylated and silenced in non-seminoma cell lines as shown by a
genome-wide methylation analysis (Noor et al., 2016).
Killian et al. in 2016 performed a lymphoid-compensated genome-
wide DNA methylation analysis of TGCTs to obtain results without the
obscuring eﬀect of lymphoid tissue within the tumors. In TGCTs they
found a PGC-like state characterized by the erasure of genomic-imprint
and demethylation of DPPA3 (STELLA), recurrent hypermethylation of
cancer-associated targets, and subtype-dependent pluripotent, germ-
line, or somatic methylation. The speciﬁc pluripotential methyl-CpH
signature (H stands for anything but G) was discovered in EC and was
lost during diﬀerentiation (Killian et al., 2016).
6. Clinical implication of TGCT epigenetics
6.1. Biomarkers
Although the serum biomarkers alpha-fetoprotein (AFP) and human
choriogonadotropin (HCG) assist malignant GCT diagnosis, AFP is
produced by yolk-sac tumor (YST) components and HCG predominantly
by choriocarcinoma (CHC); consequently, neither marker is raised in all
R. Buljubašić et al. Gene 661 (2018) 22–33
28
cases of malignant GCT nor do both show elevations in non-malignant
conditions (Murray and Nicholson, 2011). Therefore, novel preferably
noninvasively obtained biomarkers are necessary for diagnostics of
TGCTs.
Levels of methylation in the genomic DNA proved to be useful
biomarkers for risk of a particular type of tumor and can be used in the
risk assessment and molecular epidemiology (Mikeska and Craig,
2014). Recently, DNA methylation proﬁles for lung, breast, colon, and
liver diﬀerentiated cancerous tissue from normal tissue with> 95%
accuracy as well as almost all breast and colorectal cancer metastases to
the liver (Hao et al., 2017). Overall, technical prerequisites seem to be
met today for clinical diagnostics using methylation markers as has
been recently published (Bock et al., 2016).
Some of the epigenetic marks have been earlier proposed for diag-
nostics of TGCTs, but have not been employed in the clinical practice
because of some unsolved questions and doubts in the technical quality
(e.g., unmethylated XIST) (Kawakami et al., 2004; Looijenga and
Oosterhuis, 2004). Previously mentioned Eco R1 locus in intron 25 of
DNMT3A, could potentially serve as a useful epigenetic marker for
TGCT (Meikar et al., 2013). Recently, it was shown that CALCA and
MGMT are frequently methylated in non-SEs and are associated with
poor clinical outcomes in TGCT patients (Bock et al., 2016).
Pediatric malignant GCTs are biologically diﬀerent from their adult
counterparts at a genomic and protein-coding transcriptome level, but
they both display very similar microRNA expression proﬁles. Elevated
serum levels of miR-371–373 and miR-302/367 microRNAs at the time
of malignant GCT diagnosis, with levels falling after treatment may be
exploited for diagnostic and/or therapeutic purposes (Martinelli et al.,
2017). Actually a panel of four circulating microRNAs from these two
clusters (miR-371a-3p, miR-372-3p, miR-373-3p and miR-367-3p) has
been proposed as highly sensitive and speciﬁc for the diagnosis of
malignant tumors, seminoma and embryonal carcinoma. Such diag-
nostics and follow-up may reduce reliance on serial CT scanning
(Murray et al., 2015). In a most recent investigation miR-371a-3p that
accurately correlated with disease activity outperforming AFP, bHCG,
and LDH, was proposed for validation in a large-scale prospective
human study (Murray et al., 2016). However, it should be noted that
the expression of miRs in teratoma was as in normal testicular tissue
(Murray et al., 2015; Murray et al., 2016). Therefore one may presume
that growth of teratoma cannot be followed with miRNAs also in the
rare “Growing teratoma syndrome”. In this syndrome benign teratomas
develop at various extragonadal sites, after the systemic chemotherapy
for the treatment of nonseminoma of the testis with normalization of
the relevant tumor markers (Dieckmann et al., 2017).
Another promising noninvasive method for GCNIS screening seems
to be the detection of speciﬁc TGCT miRNAs in semen because speciﬁc
miRNAs associated with infertility have already been found in semen
(Elzinga-Tinke et al., 2015).
6.2. Therapy
Although TGCTs are highly treatable, thousands of men still die
from testicular cancer every year, and many challenges remain (Chieﬃ,
2016). TGCTs are highly sensitive to chemotherapy based on cisplatin,
with the exception of teratoma (Kelland, 2007). The cure rate would be
95% if the treatments were initiated in the early stages of disease
(Raghavan, 2003; Baylin and Chen, 2005). Seminoma morphology and
phenotype resembles PGCs/gonocytes and is sensitive to radiation and
chemotherapy based on platinum salts. Seminomas are mostly limited
to one testicle and have an excellent prognosis because it is possible to
cure> 90% of patients.
The resistance of TGCT to chemotherapy was associated with kar-
yotype abnormalities, single gene mutations and epigenetic regulation
of gene expression. Cisplatin acts via covalent binding to the DNA
molecule which is being recognized by proteins participating in the
process of DNA repair, leading to cell cycle arrest and apoptosis
(Sheikine et al., 2012; Cavallo et al., 2013).
Studies have identiﬁed TP53 mutation and duplication of genes that
may play a role in resistance to chemotherapy, as well as the existence
of microsatellite instability. The dysregulation of the LIN28/let-7 axis in
all malignant GCTs suggests a pathway that may be a target for the
development of novel therapeutic agents (Murray et al., 2015).
A correlation of the methylation status with tumor chemoresistance
was found. In general, undiﬀerentiated tumors, often hypomethylated,
seem to be much more sensitive to chemotherapy than well-diﬀer-
entiated tumors. In vitro, demethylation of resistant seminoma cell lines
led to increased expression of cell pluripotency markers NANOG and
POU5F1 and decreased resistance to cisplatin (Wermann et al., 2010).
RASSFIA and HIC1 promoter hypermethylation were associated with
resistance to cisplatin-based therapy of NSGCT tumors in vivo (Koul
et al., 2004). RASSF1A gene acts as a negative cell growth regulator
(Chen et al., 2003), while HIC1 encodes a transcription factor that acts
as a tumor suppressor (Koul et al., 2004). On the other hand, O‑6‑me-
thylguanine‑DNA methyltransferase (MGMT), a DNA repair enzyme gene,
and RARB gene (retinoic acid receptor gene) hypermethylation was
associated with high sensitivity to cisplatin-based therapy of NSGCT
tumors in vivo. Corresponding cell lines failed to respond to demethy-
lating or histone deacetylase inhibiting agents in activating gene ex-
pression suggesting that irreversible changes occurred in pathways that
control gene transcription (Koul et al., 2004).
Five diﬀerent EC cell-lines, including two that were cisplatin-re-
sistant, were highly sensitive to inhibition of cell growth and viability
with low doses of the DNA methylation inhibitor 5‑aza‑29‑deox-
ycytidine (5‑aza‑CdR) associated with signiﬁcantly higher levels of
DNMT3B (Beyrouthy et al., 2009). Therefore, in addition to cisplatin, a
lower dose of 5‑aza‑CdR was proposed for treatment of TGCTs. The
rationale for using 5‑aza‑CdR was that it causes the demethylation and
reexpression of the tumor suppressor genes (Juttermann et al., 1994).
The second mechanism involves apoptosis due to direct or indirect
5‑aza‑CdR-mediated DNA damage (Juttermann et al., 1994; Palii et al.,
2008). Indeed, in EC cell lines treated with 5‑aza‑CdR, ATM activation,
H2AX phosphorylation, increased expression of P21, and the induction
of genes already known to be methylated in TGCTs (MGMT, RASSF1A,
and HOXA9) was associated with decreased proliferation and survival
(Beyrouthy et al., 2009).
By the genome-wide transcriptional and promoter methylation
analyses, it was discovered that hypersensitivity of NT2/D1 testicular
cancer derived embryonal carcinoma (EC) cell lines cells to low-dose
5‑aza‑deoxycytidine involved the activation of p53 targets, repression
of pluripotency genes, and activation of genes repressed by DNA me-
thylation. Therefore, low-dose 5‑aza‑deoxycytidine therapy has been
proposed to treat those tumors that are sustained by cells with em-
bryonic stem-like properties (Biswal et al., 2012). Moreover, in a ter-
atocarcinoma model obtained by transplantation of the mouse gas-
trulating embryo to an ectopic site under the kidney capsule, the DNA
demethylating agent 5‑azacytidine diminished the growth of tumors
after treatment in vivo (Sincic et al., 2009).
Recently, in a preclinical model using a xenograft model of cispla-
tine resistant tumors, DNA methylation inhibitor guadecitabine com-
pletely abolished progression and induced complete regression of em-
bryonal carcinoma. This eﬀect has been the consequence of induction of
P53 targets and immune signatures and repression of pluripotency
genes (Albany et al., 2017) Indeed, the phase 1 clinical trial
(ClinicalTrials.gov, Identiﬁer: NCT02429466) in patients with relapsed
refractory germ cell tumors with SGI-110 (guadecitabine) in combina-
tion with cisplatin is underway (Study of the Hypomethylating Drug SGI-
110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors, n.d.). Gua-
decitabine, that represents the new generation of DNA-hypomethy-
lating agents, was so far successfully used in the treatment of the
myelodisplastic syndrome and acute myeloid leukaemia in a stage1
clinical trial, because it was well-tolerated, easily administered, and
biologically and clinically active (Issa et al., 2015).
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Overexpression of miR-199a-3p restored the expression of APC and
MGMT tumor-suppressor genes in established pluripotent human tes-
ticular embryonal carcinoma cell line Ntera2 by aﬀecting DNA me-
thylation of their promoter regions. Therefore synthetic miR-199a-3p
oligonucleotides as eﬀective hypomethylating compounds have re-
cently also been proposed in the treatment of TGCT (Chen et al., 2014).
In the end, it must be stressed that because epimutations may be
reversed (Hernandez-Vargas et al., 2009) it seems that properly tar-
geted epigenetic therapy could produce an unfavorable environment at
least for the relapse in some problematic therapeutic outcomes where
TGCTs cannot be totally destroyed by conventional therapies (Fig. 4).
Theoretically more resistant elements might rise after a treatment of
TGCT with an epigenetic drug, similarly as was discussed for the
myelodysplastic syndrome relapse. In that case better diagnostics (e.g.,
by NGS discovery of patient's resistance loci), new generations of epi-
genetic drugs, combination of epigenetic drugs (e.g., DNA hypomethy-
lating and HDACi), or other treatment options might be proposed and
employed (Carraway, 2016; Enrica Marchi et al., 2015).
7. Conclusion
TGCT's present both an interesting biological problem (Bulic-Jakus
et al., 2016; Bulić-Jakuš et al., 2006) and an important medical issue in
various human populations (Znaor et al., 2014). To ﬁnd appropriate
biomarkers (Masterson et al., 2014; Boccellino et al., 2017) and design
better therapies for TGCTs (van Agthoven et al., 2017), it is of para-
mount importance to understand the origin of the germ cell tumors in
which epigenetics has a decisive role (van der Zwan et al., 2015;
Okamoto, 2012). For example, epigenetic reprogramming in PGCs, al-
though extensively investigated in mammals with a battery of
contemporary techniques, has still been compared to a true blank slate
(Messerschmidt et al., 2014). However, recent investigations of the
methylome seem to have obtained important data on the origin of
human germ cell tumors, among which TGCTs (Rijlaarsdam et al.,
2015). It has been recently stated that epigenetic mediators, formerly
also called tumor progenitor genes, generally become epigenetically
disrupted at the earliest stages of malignancies, even before mutations.
Because they inﬂuence phenotypic plasticity during the entire neo-
plastic process, they should constitute prime targets for both prevention
and therapeutic interventions (Feinberg et al., 2016). Some of those
genes being important also for TGCT-tumorigenesis, it is possible that
they may become main therapeutic targets in TGCTs. The ongoing in-
tegrated analysis of The Cancer Genome ATLAS for GCT is underway
that is to shed light on these issues (The Cancer Genome Atlas. NIH,
NHGRI, Cancers Selected for Study, n.d.). Considering new therapeutic
approaches for TGCT, a successful targeted DNA methylation via
CRISPR-Cas9 system has recently been published (Vojta et al., 2016)
that might in future be used for epigenetic silencing of aberrantly de-
methylated epigenetic mediators (e.g., OCT). On the other hand, a
targeted demethylation for reexpression of epigenetic modulators (e.g.,
p53) that were impinged on by the favorable environment for the de-
velopment of TGCTs may be proposed (Liu et al., 2016). Although
targeted epigenome changes in cancer are in line with the con-
temporary aspirations towards precision medicine, epigenetic drugs
that target the whole epigenome are already available. Such “genomic
medicines” that may “lessen the need for precision approaches” are still
being developed and some are used in clinical trials for treatment of
various malignancies among which TGCT (Jones et al., 2016; Issa et al.,
2015).
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